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Background: In osteosarcoma, the presence of tumor-infiltrating macrophages positively correlates with patient
survival in contrast to the negative effect of tumor-associated macrophages in patients with other tumors.
Liposome-encapsulated muramyl tripeptide (L-MTP-PE) has been introduced in the treatment of osteosarcoma
patients, which may enhance the potential anti-tumor activity of macrophages. Direct anti-tumor activity of
human macrophages against human osteosarcoma cells has not been described so far. Hence, we assessed
osteosarcoma cell growth after co-culture with human macrophages.
Methods: Monocyte-derived M1-like and M2-like macrophages were polarized with LPS + IFN-γ, L-MTP-PE +/−
IFN-γ or IL-10 and incubated with osteosarcoma cells. Two days later, viable tumor cell numbers were analyzed.
Antibody-dependent effects were investigated using the therapeutic anti-EGFR antibody cetuximab.
Results: M1-like macrophages inhibited osteosarcoma cell growth when activated with LPS + IFN-γ. Likewise,
stimulation of M1-like macrophages with liposomal muramyl tripeptide (L-MTP-PE) inhibited tumor growth, but
only when combined with IFN-γ. Addition of the tumor-reactive anti-EGFR antibody cetuximab did not further
improve the anti-tumor activity of activated M1-like macrophages. The inhibition was mediated by supernatants
of activated M1-like macrophages, containing TNF-α and IL-1β. However, specific blockage of these cytokines,
nitric oxide or reactive oxygen species did not inhibit the anti-tumor effect, suggesting the involvement of other
soluble factors released upon macrophage activation. While LPS + IFN-γ–activated M2-like macrophages had low
anti-tumor activity, IL-10–polarized M2-like macrophages were able to reduce osteosarcoma cell growth in the
presence of the anti-EGFR cetuximab involving antibody-dependent tumor cell phagocytosis.
Conclusion: This study demonstrates that human macrophages can be induced to exert direct anti-tumor activity
against osteosarcoma cells. Our observation that the induction of macrophage anti-tumor activity by L-MTP-PE required
IFN-γ may be of relevance for the optimization of L-MTP-PE therapy in osteosarcoma patients.
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Osteosarcoma is the most frequent malignant bone tumor
in adolescents and young adults. Of patients with localized,
non-metastatic disease, up to 70% achieve persistent remis-
sion [1]. In contrast, prognosis of patients with advanced,
metastatic and recurrent disease is as low as 20% despite in-
tensive chemotherapy and surgery. Thus, novel therapies
are needed, especially for patients with chemotherapy-
resistant disease [2,3]. Recently, we have demonstrated that
the presence of tumor-infiltrating macrophages at the
time of diagnosis is positively correlated with a favorable
outcome of patients with osteosarcoma [4]. Hence, target-
ing tumor-associated macrophages in osteosarcoma with
macrophage-activating agents is an attractive option to
complement current anti-tumor treatments.
Macrophages are mononuclear phagocytic cells that are
involved in homeostatic, pro-inflammatory and immune
regulatory responses in the tissue [5,6]. While macrophages
can originate from blood monocytes under inflammatory
conditions, as in the classical model for macrophage
development, it has recently been revealed that under
non-inflammatory conditions tissue macrophages primarily
originate from the yolk sac and fetal liver and are main-
tained independently of hematopoietic precursors [7].
Macrophages possess great functional and phenotypic
plasticity which is often simplified by classification in
M1 and M2 phenotypes [8]. M1 macrophages are in-
volved in host defense through their bactericidal and
tumoricidal activity and pro-inflammatory cytokine produc-
tion if ‘classically-activated’ by interferon-γ (IFN-γ) and
Toll-like receptor ligands such as bacterial lipopolysacchar-
ide (LPS) [9,10]. M2 macrophages can exhibit many differ-
ent phenotypes in response to diverse stimuli such as
polarization with interleukin-10 (IL-10) or LPS. M2 macro-
phages are involved in scavenging cell debris and bacteria,
antibody-dependent phagocytosis, tissue remodeling, angio-
genesis, wound healing and immune regulation. In contrast
to ‘classically-activated’ M1 macrophages, macrophages
with an M2-like phenotype are often detected in solid tu-
mors and considered to promote tumor progression [8-11].
Macrophages constitute the majority of tumor-infiltrating
immune cells in solid tumors including osteosarcoma
[4,12]. In most tumors, the presence of macrophages repre-
sents an unfavorable prognostic factor [13]. In contrast, in
osteosarcoma as well as colorectal cancer higher numbers
of tumor-infiltrating macrophages correlate with better
survival [4,14,15]. In osteosarcoma, there was no clear asso-
ciation of good survival with an M1-like or M2-like pheno-
typic polarization of macrophages [4].
Monocytes and macrophages activated with LPS have
been implicated in anti-tumor responses for a long time
[16-21]. But while canine macrophages have been reported
to have anti-tumor activity against canine osteosarcoma
cells, comparable evidence for anti-tumor activity of humanmacrophages against human osteosarcoma cells is not
available. The anti-tumor activity of canine macrophages
was shown to be dependent on stimulation with LPS or
another bacterial cell wall constituent, i.e. muramyl dipep-
tide (MDP) or the lipophilic derivative muramyl tripeptide
phoshatidylethanolamine (MTP-PE) [22]. Application of
liposome-encapsulated MTP-PE (L-MTP-PE) in vivo im-
proved survival of dogs with osteosarcoma [23]. This
observation encouraged the addition of L-MTP-PE to the
treatment of osteosarcoma patients as a macrophage-
activating agent but did not increase event-free survival of
non-metastatic or metastatic osteosarcoma patients [1,24].
Therefore, we set out to investigate the anti-tumor ac-
tivity of human macrophages against human osteosar-
coma cells and determine whether this activity can be
manipulated. We set up an in vitro model in which the
effect of human macrophages on the growth of osteosar-
coma cells can be directly assessed by counting residual
tumor cells after a two-day co-culture with macrophages.
Using this model we demonstrate how anti-tumor activity
of M1-like macrophages and M2-like macrophages can be
induced by bacterial stimuli like L-MTP-PE and the thera-
peutic anti-EGFR antibody cetuximab, respectively.
Materials and methods
Cell lines
The osteosarcoma cell lines HOS, HOS-143b, OHS, OSA,
SAOS-2 and U2OS were obtained from the EuroBoNeT
cell line repository (2007) [25]. Cell line identity was con-
firmed by short tandem repeat DNA fingerprinting in 2012.
All cell lines were maintained in RPMI 1640 (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal calf
serum (Invitrogen) and 100 U/ml penicillin and 100 ug/ml
streptomycin (Invitrogen). All cell lines were negative for
mycoplasma infection as regularly tested by RT-PCR.
Preparation of liposomal MTP-PE
Liposomes (multi-lamellar vesicles) were prepared from
a mixture of the synthetic phospholipids 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC, 850457P)
and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS,
840035P) (both from Avanti Polar Lipids, Alabaster, Al,
USA) at a 7:3 molar ratio in chloroform by mechanical
agitation on a vortex mixer. MTP-PE (Mr 1237.5 g/mol;
Mifamurtide; Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in chloroform:methanol:water 60:36:4 (v/v/v).
5 mg of liposomes (Mr 775 g/mol) were loaded with
0.02 mg of MTP-PE (1:250 ratio). The organic solution
was dried in a rotary evaporator under reduced pressure
for one hour to obtain a dry lipid film. Afterwards, the
lipid film was rehydrated in 2.5 ml sterile PBS, resulting
in a final concentration of 6.45 nmol MTP-PE per
2 μmol/ml liposome preparation (L-MTP-PE). The lipo-
somes were passed four times through a 1 μm unipore
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somes (L-PBS) were prepared by the same procedure ex-
cept without MTP-PE addition. The z-average diameter
of the liposomes was ~350 nm with a mean zeta poten-
tial of −97 mV as measured on a Zetasizer (version 6.01)
(Malvern Instruments, Worcestershire, UK).
Monocyte Isolation and differentiation to macrophages
PBMC were separated from buffy coats of healthy adult
donors (Sanquin Blood bank, Region Southwest, Rotter-
dam, the Netherlands) by Ficoll-Hypaque density gradient
centrifugation. Monocytes were isolated from PBMC by
positive selection using anti-CD14 MicroBeads (Miltenyi
Biotech, Bergisch Gladbach, Germany). For M1-like and
M2-like macrophage differentiation, monocytes (1,5×106
per well per 3 ml of a 6-well tissue culture plate) were incu-
bated with GM-CSF (80 ng/ml; Peprotech, Rocky Hill, NJ,
USA) and M-CSF (20 ng/ml, R&D Systems, Minneapolis,
MN, USA) for seven days as previously established [10,26].
In some conditions, M1-like and M2-like macrophages
were additionally stimulated during the last day of differen-
tiation with combinations of LPS (10 ng/ml; E. coli strain
0111:B4; Sigma-Aldrich), IFN-γ (100 U/ml; Boehringer,
Mannheim, Germany), empty control liposomes (250 nmol)
(L-PBS) or liposomes (250 nmol) containing MTP-PE
(0.8 nmol, i.e., 1 μg) (L-MTP-PE) per 3 ml culture medium.
M2-like macrophages were alternatively stimulated with
IL-10 (10 ng/ml; Peprotech) during the last two days of dif-
ferentiation. The phenotype of macrophage populations
was tested in each experiment. Macrophages were devoid
of the monocyte-derived dendritic cell marker CD1a (data
not shown).
Macrophage-tumor cell co-cultures
After seven-day differentiation, culture supernatants of
macrophages were collected. Adherent macrophages were
washed in cold PBS, detached by incubation in accutase
(Sigma-Aldrich) for 30 min at 37°C and combined with
the non-adherent cell fraction. Cell scraping of firmly ad-
herent macrophages was avoided to maximize macro-
phage viability. Macrophages were seeded in 96-well flat-
bottom plates in RPMI medium at 3,000 (cell conjugate
formation assay) or 30,000 cells (tumor cell survival assay)
per well (four wells per condition) and incubated for cell
attachment. After two hours 3,000 osteosarcoma cells
were added and macrophage-tumor cell co-cultures were
incubated for two hours in cell conjugate formation assays
at a 1:1 ratio in 50 μl medium and for two hours, one day
and two days in tumor cell survival assays at a 10:1 ratio
in 100 μl medium. In some experiments, tumor cells
were coated with the chimeric monoclonal antibody
cetuximab (anti-epidermal growth factor receptor, 1 μg/ml
final concentration in co-cultures; Erbitux; Merck KGaA,
Darmstadt, Germany) or with the non-binding anti-CD20antibody rituximab (1 μg/ml; MabThera; Roche, Basel,
Switzerland) prior to the co-culture. In blocking experi-
ments, co-cultures were performed in the presence of
the soluble tumor-necrosis factor-α (TNF-α) receptor
etanercept (10 μg/ml; Enbrel; Wyeth; Madison, NJ,
USA) and TNF-α neutralizing antibody adalimumab
(10 μg/ml; Humira; Abbot; North Chicago, IL, USA),
the IL-1 receptor antagonist anakinra (10 μg/ml; Kineret;
Amgen; Thousand Oaks, CA, USA), nitric oxide species
inhibitor Nω-Nitro-L-arginine methyl ester (10 μM;
L-NAME; Sigma-Aldrich), reactive oxygen species inhibi-
tors catalase (186 μg/ml; Sigma-Aldrich) and superoxide
dismutase (4.2 μg/ml; Sigma-Aldrich).
Anti-tumor activity assay
The effect of macrophages on tumor cell survival was
assessed by enumerating tumor cells by flow cytometry
[15,27]. Adherent and non-adherent cells were harvested
after co-culture using accutase (if necessary supported
by cell scraping) and stained with anti-CD56 and anti-
CD32 to distinguish tumor cells and macrophages, re-
spectively. The complete tumor cell-macrophage suspen-
sion was analyzed by flow cytometry. Live-gated tumor
cells present at the end of the co-culture were quantified
and in each experiment compared to the number of
tumor cells grown in the absence of macrophages. In
some experiments viable tumor cell numbers were mea-
sured after their incubation in medium with 50% (v/v) of
macrophage cell-free supernatant or after their incubation
with inhibitors in the presence of macrophages. Single mea-
surements from multiple independent experiments were
combined as indicated in figure legends.
Cell conjugate formation
Tumor cell lines were labeled with CFSE (1 μM; Invitro-
gen) and incubated overnight to allow leakage of excess
CFSE. IL-10–stimulated M2-like Macrophages were co-
cultured with CFSE-labeled HOS-143b cells for two
hours at 1:1 ratio. All cells were harvested from the
culture by cell scraping and macrophages were labeled
with APC-labeled anti-CD32 antibodies. Cell conjugate
formation between macrophages and tumor cells was
analyzed by flow cytometry, assessing the percentage of
CD32+ macrophages acquiring high CFSE fluorescence
from tumor cells.
For an indication of phagocytosis, after the cell conju-
gate formation assay, CD32+ macrophages which have
acquired the fluorescent signal of CFSE+ tumor cells
were sorted by flow cytometry in one experiment. The
cells were stained with mouse anti-human HLA-DR
(TAL.1B5; Dako, Glostrup, Denmark) followed by the
Alexa-Fluor-594 goat anti-mouse IgG1 secondary anti-
body (Invitrogen) and embedded in Vectashield mount-
ing medium containing DAPI (Vectorlabs, Burlingame,
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DM5000 fluorescence microscope and LAS-AF acquisi-
tion program (Leica, Solms, Germany), detecting nuclei
in blue, HLA-DR+ macrophages in red and CFSE+ tumor
cells in green.
Flow cytometry
The following fluorochrome-labeled mouse anti-human
monoclonal antibodies were used: CD32APC (clone FLI8.26),
CD86PE (FUN-1), CD163PE (GHI/61), HLA-DRFITC (L243)
(BD Biosciences, Franklin Lakes, NJ, USA); CD56PE (NKH-
1) (Beckman Coulter, Brea, CA, USA); CD16FITC (3G8),
CD64FITC (22) (IOTEST Immunotech, Marseille, France).
Measurements were performed with the FACSCalibur (BD
Biosciences) and analyzed with the BD Cell Quest ProTM
software (version 5.2.1). Fold-expression data indicated in
histogram plots were calculated by dividing the geometric
mean fluorescence intensity (geoMFI) of antibodies by the
geoMFI of the PBS control.
Luminex assay
Cytokine production in cell-free supernatants of macro-
phage cultures was measured using the Bio-Plex Pro
Human Cytokine 27-plex group 1 panel according to
the manufacturer’s description (Bio-Rad Laboratories,
Hercules, CA, USA).
Statistical analysis
Paired student t-tests were performed to compare the
means two samples. One-way analysis of variance
(ANOVA) was performed to compare the means of
three or more samples followed by Dunnett’s or Bon-
ferroni’s multiple comparison post test to compare
samples of interest with a control sample as described
in the figure legends. Error bars represent the standard
error of the mean. A P-value of <0.05 was considered
statistically significant. All statistical analyses were per-
formed using Graphpad Prism version 5.04 (La Jolla,
CA, USA).
Results
M1-like macrophages inhibit osteosarcoma cell growth if
activated with LPS + IFN-γ
The potential of human macrophages to inhibit osteo-
sarcoma cell growth in vitro was investigated. M1-like
and M2-like macrophages were differentiated from
blood monocytes with or without the polarization
stimuli LPS + IFN-γ (for M1 and M2) or IL-10 (for M2)
as previously established [10,26,28]. The various macro-
phage subtypes were co-cultured with osteosarcoma cell
lines and after two days the residual number of viable
tumor cells was assessed by flow cytometry [15,27]. In par-
ticular M1-like macrophages pre-stimulated with LPS +
IFN-γ were able to significantly reduce tumor cell numbersof HOS-143b and OHS cells to as low as 50% and to lesser
extend of four other osteosarcoma cell lines (Figure 1, panel
A-C). The inhibition of tumor cell growth as a consequence
of macrophage addition was not yet apparent after 2 and
24 hours of co-culture but became pronounced after two
days of co-culture (Figure 1, panel D). The inhibitory effect
of activated M1-like macrophages could be titrated and was
near-maximal at >6:1 ratio (Additional file 1: Figure S1,
panel A).
M2-like macrophages stimulated with LPS + IFN-γ
showed less anti-tumor activity than LPS + IFN-γ–
stimulated M1-like macrophages, while IL-10–polar-
ized M2-like macrophages were not able to inhibit
tumor cell growth (Figure 1, panel A and B). Incuba-
tion of tumor cells with LPS + IFN-γ alone had no inhi-
biting effect (data not shown).
Induction of anti-tumor activity by M1-like macro-
phages after stimulation with LPS + IFN-γ was associated
with a more activated phenotype as indicated by the up-
regulation of CD86 and HLA-DR expression (Figure 2).
In contrast to M1-like macrophages, M2-like macro-
phages expressed CD163, a marker frequently described
for tumor-associated M2-like macrophages. LPS + IFN-
γ–stimulated M2-like macrophages showed phenotypic
similarities to LPS + IFN-γ–stimulated M1-like macro-
phages, exhibiting reduced levels of CD163 and increased
levels of CD86 and HLA-DR expression. Notably, in par-
ticular when stimulated with IL-10, M2-like macrophages
displayed high levels of FcγRII (CD32) in addition to FcγRI
(CD64) and FcγRIIIa (CD16), suggesting that IL-10–polar-
ized M2-like macrophages could exert antibody-dependent
functions as described below.
Overall, of the different macrophage populations tested,
LPS + IFN-γ–activated M1-like macrophages, resembling
‘classically-activated’ M1-like macrophages [8-10], were the
most capable of inhibiting osteosarcoma cell growth.
Liposomal muramyl tripeptide only induces anti-tumor
activity of M1-like macrophages in the presence of IFN-γ
In clinical applications, infusion of macrophage-activating
bacterial products can cause severe, detrimental toxic reac-
tions. This can be circumvented by incorporation of very
lipophilic, synthetic MTP-PE into liposomes (L-MTP-PE),
which results in rapid uptake by myeloid cells and low tox-
icity [21]. In spite of the inclusion of L-MTP-PE in clinical
trials of osteosarcoma patients, direct evidence of L-MTP-
PE to induce anti-tumor activity by human macrophages
against human osteosarcoma cells is lacking. Therefore,
it was investigated whether M1-like macrophages can be
activated by L-MTP-PE to reduce tumor cell growth. Re-
markably, only when co-stimulated with IFN-γ, L-MTP-
PE–stimulated M1-like macrophages significantly inhibited
tumor cell growth such as of HOS-143b cells and OHS
cells to as low as 45% (Figure 3, panel A and B). The
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Figure 1 Inhibition of osteosarcoma cell growth by LPS + IFN-γ–activated M1-like macrophages. Human M1-like macrophages (dark shade) and
M2-like macrophages (light shade) were pre-activated with or without LPS + IFN-γ (M1 and M2) or IL-10 (M2) and afterwards incubated with (A) HOS-143b
cells (n = 4–11) and (B) OHS cells (n = 5–12) and (C) four other osteosarcoma cell lines (n = 2–12). After two days of co-culture, tumor cell numbers were
counted by flow cytometry. Differences between one macrophage–tumor co-culture and the control, i.e. tumor cell recovery after incubation in the
absence of macrophages (white bar, set to 100%), as in panel C were statistically analyzed by paired student t-tests, *** is P < 0.001, ** is P < 0.01, * is P <
0.05, ns is not statistically significant. Differences between multiple groups as in panel A and B were statistically analyzed by ANOVA as indicated followed
by Dunnett’s post test for differences (p < 0.05) between individual co-cultures and the control as indicated by asterisks. (D) HOS-143b cell counts after 2,
24 and 48 hours co-culture with M1-like macrophages +/− LPS + IFN-γ (n = 5). All data are means of multiple experiments as indicated (n).
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rophages was as potent as by LPS + IFN-γ–activated
M1-like macrophages. In contrast, M1-like macrophages
stimulated with MTP-PE-loaded liposomes alone, empty
liposomes (L-PBS) or empty liposomes in combination with
IFN-γ failed to inhibit tumor cell growth. Moreover, only
when co-stimulated with IFN-γ, L-MTP-PE–stimulated
M1-like macrophages exhibited an activated phenotype by
CD86 and HLA-DR up-regulation similar to LPS + IFN-γ–
activated M1-like macrophages (Figure 3, panel C). In
conclusion, L-MTP-PE stimulation induced substantial
anti-tumor activity of M1-like macrophages but only after
co-stimulation with the pro-inflammatory cytokine IFN-γ.
Soluble factors produced by M1-like macrophages after
LPS + IFN-γ and L-MTP-PE + IFN-γ activation inhibit tumor
cell growth
Next, the mechanisms involved in the strong anti-tumor
effect of LPS + IFN-γ–activated and L-MTP-PE + IFN-γ–activated M1-like macrophages were investigated. Incu-
bation of osteosarcoma cells in medium with cell-free
supernatant of activated M1-like macrophages reduced
tumor cell growth to similar levels as activated M1-like
macrophages themselves (Figure 4, panel A). In contrast,
supernatant from non-activated M1-like macrophages
did not reduce tumor cell growth. The inhibitory effect of
macrophage supernatant was dose-dependent (Additional
file 1: Figure S1, panel B). These data indicate that both
LPS + IFN-γ–activated and L-MTP-PE + IFN-γ–activated
M1-like macrophages produced soluble factors that inhib-
ited osteosarcoma cell growth. Therefore we measured the
levels of soluble factors produced by activated macrophages
alone and after two-day co-culture with the tumor cells.
Activation of M1-like macrophages with LPS + IFN-γ en-
hanced the production of the pro-inflammatory cytokines
IL-1β, IL-6, IL-12p70, TNF-α, CXCL10 (IP-10) and CCL5
(Rantes), while CCL2 (MCP-1), CCL3 (MIP-1α) and CCL4
(MIP-1β) remained unchanged amongst a panel of 27
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Figure 2 Phenotypes of M1-like and M2-like macrophages. Surface expression of Fcγ receptors (CD16, CD32 and CD64), HLA-DR, CD86 and
CD163 on the various M1-like and M2-like macrophage populations was analyzed by flow cytometry. Fold change of geoMFI of specific
antibody stainings (bold solid line) compared to PBS control (light shade) is indicated in the FACS histogram plots. Representative data of
three experiments are depicted.
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MTP-PE + IFN-γ–activated M1-like macrophages displayed
a similar cytokine profile except for lower levels of IL-
12p70.
Since TNF-α was reported to be able to confer anti-
tumor effects [29] and was also produced by both LPS +
IFN-γ–activated and L-MTP-PE + IFN-γ–activated M1-
like macrophages during the co-culture (Figure 4, panel
C), a role for TNF-α in the inhibition of osteosarcoma
cell growth was examined. Blocking of TNF-α during
the co-culture of macrophages and tumor cells by the
soluble TNF receptor etanercept combined with the
TNF-α neutralizing antibody adalimumab did not pre-
vent the inhibition of cell growth of HOS-143b and
OHS cells by LPS + IFN-γ–activated M1-like macro-
phages or supernatants derived from these macrophages
(Figure 4, panel D and data not shown). Blocking
of TNF-α did also not prevent the inhibiting effects
of L-MTP-PE + IFN-γ–activated M1-like macrophages
(data not shown). Moreover, blocking of IL-1 receptor,
combined blocking of TNF-α and IL-1 receptor, or in-
hibition of nitric oxide and reactive oxygen species did
not significantly interfere with the inhibition of tumor
cell growth by activated macrophages (Figure 4, panel
D). None of the tested inhibitors affected tumor cell
growth as compared to tumor cells incubated in the ab-
sence of inhibitors.
These results indicate that the inhibition of osteosar-
coma cell growth by activated M1-like macrophages wasmediated by soluble factors induced by macrophage acti-
vation in a TNF-α/IL-1–independent manner.
IL-10–stimulated M2-like macrophages can inhibit growth
of osteosarcoma cells in an antibody-dependent manner
Both M1-like and M2-like macrophages have been detected
in osteosarcoma lesions [4]. Hitherto, IL-10–stimulated
M2-like macrophages were unable to inhibit osteosarcoma
cell growth. In a previous study it has been shown that IL-
10-polarized M2-like macrophages internalized antibody-
coated B cell lymphoma cells [28]. Since IL-10–stimulated
M2-like macrophages exhibited the highest expression of
FcγR in our experiments, we investigated whether these
macrophages are able to form cell conjugates with and
internalize osteosarcoma cells in an antibody-dependent
manner as a potential anti-tumor mechanism. After two-
hour co-culture of IL-10–stimulated M2-like macrophages
and CFSE-labeled HOS-143b cells, CD32+ M2-like macro-
phages acquiring the fluorescent signal of HOS-143b cells
were analyzed by flow cytometry, as similarly described be-
fore [28,30]. If HOS-143b cells were coated with the anti-
EGFR antibody cetuximab, the percentage of CD32+CFSE+
macrophages was increased, indicative for cell conjugate
formation between macrophages and tumor cells (Figure 5,
panel A). Furthermore, FACS-sorted CD32+CFSE+ macro-
phages (upper right quadrant) were analyzed by immuno-
fluorescence microscopy and contained tumor cells bound
to macrophages as well as tumor cells internalized by mac-
rophages (Figure 5, panel B).
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Figure 3 M1-like macrophages stimulated with L-MTP-PE require IFN-γ for anti-tumor activity. M1-like Macrophages were activated with
LPS + IFN-γ, L-MTP-PE + IFN-γ, L-MTP-PE alone, L-PBS + IFN-γ or L-PBS alone. Tumor cell numbers of (A) HOS-143b (n = 3–5) and (B) OHS (n = 2–4)
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post test as indicated. (C) Surface expression of Fcγ receptors (CD64, CD32 and CD16), HLA-DR and CD86 was analyzed on M1-like macrophages
after activation with LPS + IFN-γ, L-MTP-PE + IFN-γ, L-MTP-PE alone, L-PBS + IFN-γ or L-PBS alone. Representative data of two experiments
are depicted.
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interaction between tumor cells and macrophages can re-
sult in inhibition of tumor cell growth. Indeed, IL-10–stim-
ulated M2-like macrophages substantially inhibited growth
of two osteosarcoma cell lines (2/6) such as HOS-143b to
as low as 50% if coated with cetuximab (Figure 5 panel C
and data not shown). There was not such an inhibitingeffect when HOS-143b cells were treated with the isotype-
matched, non-tumor-binding anti-CD20 antibody rituxi-
mab. In contrast, IL-10–stimulated M2-like macrophages
failed to inhibit cell growth of (or form cell conjugates
with) cetuximab-coated OHS cells despite high levels of
EGFR expression [31], indicating that additional cell char-
acteristics play a role in determining the sensitivity of
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Figure 4 Tumor growth inhibition by activated M1-like macrophages is mediated by soluble factors. (A) HOS-143b cells were incubated
with M1-like macrophages (pre-activated +/− LPS + IFN-γ or L-MTP-PE + IFN-γ) (no pattern) or with cell culture supernatant from these macrophages
(hatched pattern) for two days. Tumor cell numbers were analyzed relative to the control (ANOVA and Dunnett’s post test n = 3–8). The
cytokine/chemokine profile of M1-like macrophages was assessed in cell-free supernatants obtained (B) after macrophage activation or (C)
after macrophage activation and subsequent two-day co-culture with HOS-143b cells. Data of IL-1β, IL6, IL-12p70, TNF-α, CXCL10 (IP-10),
CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β) and CCL5 (Rantes) were acquired by Luminex assays (n = 2–3). There was no cytokine/chemokine production
by tumor cells alone. Compared to activated macrophages alone the co-culture with tumor cells did not enhance cytokine/chemokine production (data
not shown). (D) HOS-143b cells were incubated with/without LPS + IFN-γ-activated M1-like macrophages in the presence or absence of inhibitors against
TNF-α (by neutralizing antibody and soluble TNF receptor), IL-1 receptor (by IL-1Ra), TNF-α and IL-1 receptor, nitric oxide (by L-NAME) or reactive oxygen
species (by catalase and SOD). For each set of inhibitor experiments (n = 3–6) tumor cell numbers of the following conditions are depicted: after co-culture
with activated macrophages (filled bar), tumor cells alone with inhibitors (white bar hatched pattern), after co-culture with activated macrophages with
inhibitors (filled bar hatched pattern), analyzed relative to tumor cells only without inhibitors (white bar). There was no significant difference
between co-cultures with and without inhibitors, or between tumor cells alone and co-cultures with inhibitors, whereas differences between tumor cells
alone and co-cultures with/without inhibitors were statistically significant (P < 0.05, ANOVA and Bonferroni’s post test).
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Figure 5 Antibody-dependent tumor cell growth inhibition by IL-10–polarized M2-like macrophages. (A) CFSE-labeled HOS-143b cells
coated with anti-EGFR cetuximab or non-binding anti-CD20 rituximab were incubated with IL-10–stimulated M2-like macrophages for two hours.
Cell conjugate formation was evaluated by flow cytometry, assessing CD32+ macrophages acquiring high CFSE fluorescence of the tumor cells.
Representative data of two experiments are depicted. (B) In one experiment, CD32+CFSE+ cells (upper right quadrant in lower panel A) were
sorted by flow cytometry and examined by Immunofluorescence microscopy, detecting HLA-DR-stained macrophages in red (lower left), CFSE+
tumor cells in green (lower right) and DAPI-stained cell nuclei in blue (upper right) and composites (upper left). (C) HOS-143b (n = 4–7) and (D)
sOHS (n = 5–8) cells were coated with cetuximab (hatched pattern) or rituximab (control, no pattern) and incubated with M2-like macrophages
pre-stimulated with or without IL-10. After two days tumor cell numbers were analyzed by ANOVA and Dunnett’s post test.
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activity (Figure 5, panel D and data not shown). In the ab-
sence of macrophages, there was no inhibitory effect by
cetuximab on osteosarcoma cells (Figure 5, panel C and D)
[31]. Inhibition of tumor cell growth by LPS + IFN-γ–stim-
ulated M1-like macrophages was not further increased by
cetuximab (data not shown).
Hence, at least for some cell lines, IL-10–stimulated
M2-like macrophages have the potential to inhibit osteo-
sarcoma cell growth in an antibody-dependent manner
with similar efficacy as antibody-independent inhibition
by activated M1-like macrophages.
Discussion
In this report, we describe for the first time that human
macrophages can interfere with the growth of human
osteosarcoma cells. Significant induction of anti-tumor
activity of human M1-like macrophages by liposomal
muramyl tripeptide required co-stimulation with pro-
inflammatory IFN-γ. Inhibition of osteosarcoma cell
growth by activated M1-like macrophages was mediated
by soluble factors which were induced upon macro-
phage activation before interaction with tumor cells. In
addition, we report that IL-10–polarized M2-like macro-
phages could exert anti-tumor activity against some osteo-
sarcoma cell lines in an antibody-dependent manner.
More than 100 years ago it has been observed by Busch,
Fehleisen, Bruns and others that bacterial infections can
result in tumor regression accompanied by febrile inflam-
matory responses which presumably mediated the anti-
tumor effects [32,33]. These findings pioneered the first ex-
tensive immunotherapy of bone sarcoma patients by Coley,
administering heat-inactivated bacterial preparations with
considerable but disputed remission rates. The anti-tumor
effect was probably, at least in part, linked to the pro-
inflammatory response of innate immune cells such as
macrophages to bacterial constituents like LPS [33,34]. An-
other bacterial cell wall component, muramyl dipeptdide
(MDP) has originally been discovered as the minimal
(synthetically-derived) moiety of peptidoglycan which can
substitute for mycobacteria in Freund’s complete adjuvant
[35]. MTP-PE is a lipophilic, synthetic derivate of MDP
which has low toxicity and enhanced macrophage-
activating properties if incorporated in liposomes (L-MTP-
PE) [21]. To mimic bacterial infections and trigger
macrophage activation, L-MTP-PE has been included
in the treatment of osteosarcoma patients [1]. Our ob-
servation that the anti-tumor effect of L-MTP-PE–
stimulated macrophages was dependent on IFN-γ is
noteworthy in this respect. IFN-γ was originally de-
scribed as macrophage-activating factor [36]. ‘Priming’
of macrophages by IFN-γ may enhance liposome up-
take and improve the response to bacterial compo-
nents by, for instance, intracellular NOD2, which is thereceptor for MDP and presumably MTP-PE [21,37-39].
The significance of IFN-γ observed in our experiments
reproduces previous studies using different tumor cells
which showed that activation of human/murine mono-
cytes/macrophages by L-MTP-PE was enhanced by simul-
taneous or preceding stimulation with IFN-γ [17,21,38].
Furthermore, addition of IFN-γ to L-MTP-PE was reported
to improve survival and inhibit metastases in murine renal
adenocarcinoma [40]. Altogether, the clinical efficacy of
L-MTP-PE addition in the treatment of osteosarcoma pa-
tients may be improved by the inclusion of a macrophage-
priming signal like IFN-γ.
This raises the question how such a macrophage-priming
factor could be safely introduced in the osteosarcoma
microenvironment. IFN-γ levels could be increased by local
or systemic IFN-γ therapy as applied in patients with can-
cers or mycobacterial infections [41,42]. To target the same
macrophages with IFN-γ as with L-MTP-PE, IFN-γ could
be incorporated in MTP-PE-containing liposomes which
are then both efficiently internalized by phagocytic cells
such as tumor-resident or tumor-infiltrating macrophages.
This approach is supported by murine studies in which the
incorporation of IFN-γ into MTP-PE–containing liposomes
enhanced the tumoricidal activity of macrophages as com-
pared to liposomal MTP-PE alone [21,43]. Alternatively,
lymphocytes such as NK cells activated to secrete IFN-γ
and recruited to tumor sites might enhance local IFN-γ
production [44].
Inhibition of osteosarcoma cell growth was mediated
by soluble factors which were produced by activated
M1-like macrophages before interaction with the tumor
cells. It is noteworthy that the macrophages themselves
as well as their secreted factor reached a maximal effect
on inhibiting tumor cell numbers to about 50%. Inhib-
ition of cell growth required time and became only evi-
dent after more than one day. Altogether these data
suggest that the inhibitory factor may either limit growth
of the tumor cells to a certain maximal cell density or
that this factor has a delayed cytotoxic effect. However,
because a cytotoxic effect is expected to become evident
sooner, an anti-proliferative effect of this factor is more
likely. Similar to our results, inhibition of colorectal
cancer cells by an unidentified soluble factor of macro-
phages has recently been reported [45].
In our experiments, bacterial and pro-inflammatory stim-
uli induced the strongest inhibition of tumor cell growth
by M1-like macrophages. Therefore, such macrophage-
activating therapies may primarily be effective in tumor
types that contain M1-like macrophages [14,15]. Most
tumors contain high numbers of potentially ‘pro-tumor’
immune regulatory M2-like macrophages. The successful
adjuvant therapy with Bacillus Calmette-Guérin in pa-
tients with bladder cancer may involve the activation
of pro-inflammatory M1-like macrophages, but might
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phages [46,47]. Therefore, several studies have considered
depleting macrophage numbers or inhibiting macrophage
recruitment to the tumor [11,48,49]. Instead, in our experi-
ments, IL-10–polarized M2-like macrophages could be in-
duced to inhibit osteosarcoma cell growth if the tumor cells
were coated with the therapeutic anti-EGFR antibody
cetuximab. Antibody-dependent cell conjugate formation
and inhibition of tumor cell growth were only observed for
half of the osteosarcoma cell lines despite significant EGFR
expression [31]. Hence, to improve antibody-dependent
anti-tumor activity by M2-like macrophages, it would be re-
quired to elucidate additional parameters besides surface
antigen expression that determine inhibition of tumor cell
growth by macrophages. Expression of CD47 on tumors
cells has been described to block phagocytic function by
binding to SIRP1α expressed on phagocytic cells [50]. How-
ever, CD47 gene expression was not significantly different
between the cell lines (inhibited or not inhibited by M2-like
macrophages), as concluded from previously published
genome-wide gene profiling data of osteosarcoma cell lines
[4] (data not shown).
The potential of antibody-dependent anti-tumor activity
by macrophages has been shown to mediate anti-tumor re-
sponses in murine lymphoma models [51,52]. In humans,
the addition of rituximab therapy to patients with follicular
lymphoma can counteract the non-favorable prognostic
factor of high macrophage counts in the tumor [53].
We have previously demonstrated that the cytotoxic
activity of NK cells can be enhanced and directed
to osteosarcoma cells by anti-EGFR cetuximab [31].
Since macrophages abundantly infiltrate osteosarcoma le-
sions, antibody-dependent inhibition of osteosarcoma cell
growth by macrophages may be an additional anti-tumor
mechanism of cetuximab.
The recent finding that anti-CD40 therapy can induce
anti-tumor activity in mice and humans independently
of T cells but presumably via activating macrophages has
revived the role of macrophages in anti-tumor responses
[54]. Overall, activation of macrophages by e.g. L-MTP-
PE in the presence of IFN-γ, and/or treatment with
tumor-reactive antibodies may in particular be advanta-
geous in tumors like osteosarcoma that have a high con-
tent of infiltrating macrophages.Additional file
Additional file 1: Figure S1. Inhibition of tumor cell growth by activated
M1-like macrophages is dose-dependent. (A) HOS-143b and OHS cells were
incubated with increasing numbers of LPS+IFN-γ–activated M1-like
macrophages as indicated by the macrophage:tumor ratios from 0 to
20. (B) HOS-143b and OHS cells were incubated with increasing
amounts of cell-free culture supernatant of LPS+IFN-γ and L-MTP-PE
+IFN-γ–activated M1-like macrophages as indicated by the percentage
of culture supernatant present during tumor cell culture. Of note,supernatant from LPS+IFN-γ-activated M1-like macrophages was slightly
more potent in tumor growth inhibition than supernatant of L-MTP-PE+IFN-γ
activated M1-like macrophages.
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